Organon's Q3: Biosimilars Shine, Nexplanon Struggles
Update: 2025-11-17
Description
Organons Q3 results exceeded expectations, with $1.60 billion in revenue and $1.01 in adjusted earnings per share. The biosimilars division, particularly Hadlima, drove growth, while cost management strategies also contributed. However, the U.S. Womens Health segment, including Nexplanon, faced challenges due to policy changes. Despite these issues, Organons diverse product portfolio was highlighted as a strength. During the earnings call, questions were raised about the respiratory business and sales investigation, to which management responded with details on Vtamas safety profile and the completion of remediation. Investors will now focus on biosimilars adoption, new product launches, Nexplanon sales stabilization, and debt reduction following a recent divestiture.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
